Modulation of the transforming growth factor β1 by vitamin E in early nephropathy

Medical Principles and Practice

Volumn 14, Issue 6, 2005, Pages 422-429

  Cojocel, C ^a   Al Maghrebi, M ^a   Thomson, M S ^a   Rawoot, P ^a   Raghupathy, R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Diabetic nephropathy; Lipid peroxidation; TGF 1 mRNA; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; FRUCTOSAMINE; GLUCOSE; GLUTATHIONE; INSULIN; LYSOZYME; MALONALDEHYDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMURIA; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; KIDNEY CORTEX; MALE; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PLASMA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; URINE;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FRUCTOSAMINE; GLUTATHIONE; GLYCOSURIA; KIDNEY; MALE; MALONDIALDEHYDE; MURAMIDASE; OXIDATIVE STRESS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN E;

EID: 26644439041     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088116     Document Type: Article

References (40)

1. Schena FP: Epidemiology of end-stage renal disease: internal comparisons of renal replacement therapy. Kidney Int 2000;57:S-39-S-45.
2. Friedman EA: Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1999;14(suppl 3):1-9.
3. Biesenbach G, Janko O, Zazgomik J: Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transpl 1994;9:1097-1102.
4. Sheehy MJ: HLA and insulin-dependent diabetes. A protective perspective. Diabetes 1992;41:123-129.
5. Wirta O, Pastemack A, Laippala P, Turjanama V: Glomerular filtration rate kidney size after six years of disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol 1996;45:10-17.
6. Porte D Jr, Schwartz MW: Diabetes complications: why is glucose potentially toxic? Science 1996;272:699-700.
7. Maillard LC: Action des acides aminés sur les sucres: formation des mélanoïdines par voie méthodique. C R Acad Sci 1912;154:66.
8. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl Med 1998;318:1315-1321.
9. Baynes JW: Perspectives in diabetes. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
10. Meng J, Sakata N, Imanaga Y, Tachikawa Y, Chihara J, Takebayashi S: Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure. Clin Nephrol 1991;51:280-289.
11. Monnier VM, Nagaraj RH, Portero-Otin M, Glomb M, Elgawish AH, Sell DR, Friedlander MA: Structure of advanced Maillard reaction products and their pathological role. Nephrol Dia Transplant 1966;11(suppl 5):20-26.
12. Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, Neumann A, Schinzel R, Cunningham AM: Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerizaton of beta-amyloid peptide. Biochim Biophys Acta 1997;1360:17-29.
13. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G: Early AGEing and Alzheimer's. Nature 1995;374:316.
14. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-219.
15. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995;44:1139-1146.
16. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405.
17. Border WA, Noble NA: Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998;54:1390-1391.
18. Cojocel C, Laeschke KH, Inselmann G, Baumann K: Inhibition of cephaloridine-induced lipid peroxidation. Toxicology 1985;35:295-305.
19. Agardh E, Hultberg B, Agardh C: Effects of inhibition of glycation and oxidative stress on the development of cataract and renal vessel abnormalities in diabetic rats. Curr Eye Res 2000;21:543-549.
20. Al-Awadi FM, Al-Adnan MS: Structural changes in glomeruli and proteinuria in streptozotocin diabetic rats. Histol Histopathol 1989;4:129-135.
21. Schacterle GR, Pollack RL: A simplified method for quantitative assay of small amounts of protein in biological material. Anal Biochem 1973;51:654-655.
22. Cojocel C, Baumann K: Renal handling of endogenous lysozyme in the rat. Ren Physiol 1983;6:258-265.
23. Viner BM, Kisel VL, Krendal PP, Rubtsova ER: A modification of ortho-toluidine method for determining glucose in the blood. Eksp Klin Farmakol 1973;56:62-64.
24. Johnson RN, Metcalf PA, Backer JR: Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1982;127:87-95.
25. Backer JR, Metcalf PA, Johnson RN: Use of protein-based standards in automated colorimetric determinations of fructosamine in serum. Clin Chem 1985;31:1550-1554.
26. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
27. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-312.
28. Dogra S, Filser JG, Cojocel C, Greim H, Regel U, Oesch F, Robertson LW: Long-term effects of commercial and congeneric polychlorinated biphenyls on ethane production and malondialdehyde levels, indicators of in vivo lipid peroxidation. Arch Toxicol 1988;62:369-374.
29. Tsunoda S, Yamabe H, Osawa H, Kaizuka M, Shirato K, Okumura K: Cultured rat glomerular epithelial cells show gene expression and production of transforming growth factor-β: expression is enhanced by thrombin. Nephrol Dial Transplant 2001;16:1776-1782.
30. Junod A, Lambert AE, Atauffacher W, Renold AE: Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest 1969;48:2129-2139.
31. Montilla PL, Vargas JF, Tunez IF, Munoz de Agueda MC, Valdelvira ME, Cabrera ES: Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin. Pineal Res 1998;25:94-100.
32. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F: Pharmacological doses of vitamin E improves insulin action. Am J Clin 1993;57:650-656.
33. Lehmann R, Schleicher ED: Molecular mechanisms of diabetic nephropathy. Clin Chim Acta 1993;297:135-144.
34. Baumann K, Cojocel C: Microperfusion and clearance studies on renal protein reabsorption. Contr Nephrol 1981;24:8-17.
35. Koya D, Haneda M, Kikkawa R, King GL: d-alpha-tocopherol treatment prevents glomerular dysfunction in diabetic rats through inhibition of protein kinase C-dicylglycerol pathway. Biofactors 1998;7:69-76.
36. Hirnerova E, Krahulec B, Strbova L, Stecova A, Dekret J, Hajovska A: Effect of vitamin E therapy on progression of diabetic nephropathy. Vnitr Lek 2003;49:529-534.
37. Koya D, Hayashi K, Kitada M, Kashiwagi A, Haneda M: Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003;14:S250-S253.
38. Kedziora-Kornatowska K, Szram S, Kornatowski T, Szaduijkis-Szadurski L, Kezdiora J, Bartosz G: Effects of vitamin E and vitamin C supplementation on oxidative state and renal glomerular basement membrane thickness in diabetic kidneys. Nephron Exp Nephrol 2003;95:e134-e143.
39. de Caestecker M: The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004;15:1-11.
40. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.